MarginsXMarginsX
Home › Markets › Health Care › ZYME

Zymeworks Inc. (ZYME)

ZYME trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$26.45
+0.80% on the day
Market cap
$1.8B
Small cap
Revenue · 2025
$106.0M
+38.9% on 2024
Net income · 2025
-$81.1M
-76.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/0001937653-26-000015-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerZYME on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001937653
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$106.0M
Net income-$81.1M
Operating income-$92.5M
Net margin-76.6%
Operating margin-87.3%
Revenue growth+38.9%
Cash$41.2M
Total assets$346.5M
P/E (computed)Net income was not positive
P/S (computed)17.2×

Warning signs

Cash runway
10.8 months
$100.5M cash at September 30, 2026
Share count, 1 year
-7.8%
2025-11-04 to 2026-11-06 · -1.4% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$4.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$100.5M cash; operating cash flow -$28.0M a quarter.Report 2026-09-30
Shares outstanding69,030,691 (2026-11-06); 74,836,534 a year earlier; 70,001,987 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Vancouver, CanadaPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$256.5M$173.7M-$24.0M$100.5M$338.9M$266.0M10-Q 2026-11-09
Q2 2026
2026-06-30
$4.6M-$45.0M-$31.9M$179.4MNo debt tags$37.1M10-Q 2026-08-06
Q1 2026
2026-03-31
$2.4M-$44.2M-$45.7M$244.3MNo debt tags$81.3M10-Q 2026-05-07
Q4 2025
2025-12-31
$2.5M-$41.2M-$10.3M$41.2MNo debt tags$106.0M10-K 2026-03-02
Q3 2025
2025-09-30
$27.6M-$19.6M-$31.4M$64.8MNo debt tags$134.5M10-Q 2026-11-09
Q2 2025
2025-06-30
$48.7M$2.3M$12.1M$98.3MNo debt tags$122.9M10-Q 2026-08-06
Q1 2025
2025-03-31
$27.1M-$22.6M-$3.4M$76.2MNo debt tags$93.4M10-Q 2026-05-07
Q4 2024
2024-12-31
$31.0M-$23.5M-$41.5M$66.1MNo debt tags$76.3M10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-08-02
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-10-26

Source: SEC EDGAR submissions feed, 343 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-11.4%
1 month+4.7%
3 months+1.9%
Year to date-0.3%
1 year+41.8%
From 52-week high-16.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ETONEton Pharmaceuticals Inc.$63.88-0.08%$1.8B
AGIOAgios Pharmaceuticals Inc.$30.15-4.56%$1.8B
ZBIOZenas BioPharma Inc.$27.93-0.29%$1.9B
TRVITrevi Therapeutics Inc.$13.29-2.64%$1.9B
BRVEBraveheart Bio Inc.$19.49-0.66%$1.8B
STOKStoke Therapeutics Inc.$26.63-0.19%$1.7B
MRVIMaravai LifeSciences Holdings Inc.$7.40-1.86%$1.9B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier